PSQ – Morgan Stanley rates the stock as Overweight

Morgan Stanley observes the economics for Pacific Smiles are improving, with break-even being achieved in nine months in some centres compared with the previous target of 12 months.

The company expects 20-25 new centres in FY22 and the broker believes the acceleration in the roll-out and the backing of private health insurers makes this a unique asset in the Australian market.

Overweight retained. Target is $3.20. Industry view: In-line.

Sector: Health Care Equipment & Services.


Target price is $3.20.Current Price is $2.50. Difference: $0.70 – (brackets indicate current price is over target). If PSQ meets the Morgan Stanley target it will return approximately 22% (excluding dividends, fees and charges – negative figures indicate an expected loss).



About Broker News

FNArena's Australian Broker Call, is your daily news report on the latest recommendation, valuation, forecast and opinions recently published by Stockbrokers.

View more articles by Broker News →